SAN DIEGO — Victory Pharma Inc. has completed the acquisition of substantially all of the assets of MiddleBrook Pharmaceuticals Inc.

With the deal, terms of which weren’t disclosed, Victory Pharma has expanded its product portfolio with the addition of anti-infective products Moxatag and Keflex, along with the Pulsys drug delivery technology platform.

Victory added that the product additions complement its current products, such as Naprelan, which the company markets to primary care and specialist physicians.

"This acquisition reflects our strategy of leveraging our existing commercial infrastructure to expand our portfolio of marketed products," Matt Heck, president and chief executive officer of Victory Pharma, said in a statement. "The addition of these products balances our portfolio nicely, as Naprelan’s highest period of utilization is in the spring and summer, while Moxatag’s utilization peaks during the flu season. And we believe Moxatag will substantially benefit from our management team’s prior, successful experience marketing anti-infective products."

Westlake, Texas-based MiddleBrook had announced at the end of April that it filed for Chapter 11 bankruptcy protection.

Moxatag is the only Food and Drug Administration-approved, once-daily formulation of amoxicillin and is indicated for the treatment of tonsillitis and/or pharyngitis. It uses the Pulsys technology to deliver drug at set intervals over a 24-hour period, whereas other amoxicillin products require multiple-times-daily dosing.